Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...

Leading global drugmakers such as MSD Pharmaceuticals, Novartis, AstraZeneca, and Pfizer stand to benefit as it opens new ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

With little fanfare, the Biden administration stacked a critical committee that helps set U.S. vaccination policy with new ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...